- Meira GTx Holdings plc MGTX announced positive clinical data from the ongoing Phase 1 AQUAx study of AAV2-hAQP1 for Grade 2/3 Radiation-Induced Xerostomia (RIX), Dry Mouth.
- Clinically meaningful improvements in xerostomia symptoms were consistently reported across two validated PROs assessing xerostomia symptom severity.
- Significant increases in total salivary flow rates were observed after treatment, providing objective evidence for the biological activity of AAV2-hAQP1 treatment.
- Related: MeiraGTx publishes encouraging gene therapy data from eye disease study.
- Early long-term follow-up data suggest durability of improvement beyond 2 years post-treatment.
- About 18/24 or 75% of all participants treated unilaterally and bilaterally reported that dry mouth symptoms were “better” after treatment.
- Each of these 18 participants rated the changes in xerostomia scores as “important” or “very important” (a score of 2 or more).
- In the overall cohorts, the mean improvement in score was greater for bilateral participants than for unilateral participants.
- Price promotion: MGTX shares are down 4.35% to $1.10 on the most recent check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
